Player Avatar zzlangerhans (99.85) Submitted: 8/30/2010 12:29:56 PM : Outperform Start Price: $13.56 CYTK Score: -75.97

I could just as easily have entered a limit order to green thumb Cytokinetics at 2, since I'm not strongly sensing a bottom here, but I'm annoyed with my growing list of limit orders that aren't getting activated. That's a good enough reason for a market order, isn't it?I've red-thumbed Cytokinetics twice before only to journey deep into the red zone before eventually escaping with positive scores. It's a good example of how perseverance in CAPS will lead you to a high rating even if your choices are short-term contrarian indicators. We'll see if my first green thumb can have a similar effect.Subsequent to the death of the KSP inhibitor oncology program, Cytokinetics is now a pure "muscle contractility" developmental pharma. Their unique pipeline increases the likelihood of both breakout success and abject failure.Short-term catalysts are preliminary phase IIa data for skeletal muscle troponin activator CK-2017357 and initiation of a phase IIb trial for cardiac myosin activator CK-1827452. Considering prior PR successes, I'm expecting the company to successfully spin very preliminary CK-2017357 data positive with a modest bump in share price before the end of 2010. An uptick in the burn rate has significantly eroded the beefy cash position this year, so if the share price goes back over 4 on inflated optimism I'd watch out for a dilutive financing.Another unique feature of Cytokinetics is that CEO Robert Blum appears to wear two large earrings: Go figure.

Featured Broker Partners